Skip to main content
Log in

Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of parkinson’s disease

  • Published:
Molecular Neurobiology Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is characterized by a progressive loss of substantia nigra pars compacta (SNc) neurons. The onset of clinical symptoms only occurs after the degeneration has exceeded a certain threshold. In most of the current 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) nonhuman primate models, nigrostriatal lesions and the onset of PD symptoms are the result of an immediate neuronal degeneration in the SNc caused by acute injection of the toxin. In order to develop a model that more closely mimics the degeneration pattern of human PD, we eventually established a protocol that produces a progressive parkinsonian state by treating monkeys repeatedly with MPTP for 15 ± 2 d. Mean onset of parkinsonian symptoms occurred after 13.2 d of treatment. At this time, 56.8 ± 6.3% of tyrosine hydroxylase immunoreactive neurons and 75.2 ± 6.2% of Nissl-stained cells remained in the SNc. Striatal dopamine transporter (DAT) binding and dopamine (DA) content decreased to 19.7 ± 4.9% and 18.2 ± 5.6% of untreated monkeys. Parallel 123I-PEI single-photon emission computed tomography (SPECT) imaging in living animals showed a similar decrease in striatal DAT binding. In this article, we examine how this and other chronic MPTP models fit with human pathology.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., and Kopin I.J. (1986) Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of MPTP. Life Sci. 39, 7–16.

    Article  PubMed  CAS  Google Scholar 

  • Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., and Seitelberger F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 20, 415–455.

    Article  PubMed  CAS  Google Scholar 

  • Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease, Nat. Neurosci. 3, 1306–1312.

    Google Scholar 

  • Bezard E., Boraud T., Bioulac B., and Gross C. (2000) Evolution of the multiunit activity of basal ganglia in the course of a dynamic experimental parkinsonism, in The Basal ganglia VI (Graybiel A., ed.), Kluwer Academic Publishers, Norwell, 2001, pp. 107–116.

    Google Scholar 

  • Bezard E., Crossman A.R., Gross C.E., and Brotchie J.M. (2001a) Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson’s disease. FASEB J. 10.1096, 1092–1094.

    Google Scholar 

  • Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., et al. (2001b) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson’s disease. J. Neurosci. 21, 6853–6861.

    PubMed  CAS  Google Scholar 

  • Bezard E. and Gross C.E. (1998) Compensatory mechanisms in experimental and human parkingsonism: towards a dynamic approach. Prog. Neurobiol. 55, 93–116.

    Article  PubMed  CAS  Google Scholar 

  • Bezard E., Imbert C., Deloire X., Bioulac B., and Gross C. (1997) A chronic MPTP model reproducing the slow evolution of Parkinson’s disease: evolution of motor symptoms in the monkey. Brain Res. 766, 107–112.

    Article  PubMed  CAS  Google Scholar 

  • Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., and Brotchie J.M. (2001c) Upregulation of Striatal Preproenkephalin Gene Expression Occurs Before the Appearance of Parkinsonian Signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkeys. Neurobiol. Dis. 8, 343–350.

    Article  PubMed  CAS  Google Scholar 

  • Brooks D.J., Ibanez V., Sawle G.V., Quinn N., Lees A.J., Mathias C.J., et al. (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol. 28, 547–555.

    Article  PubMed  CAS  Google Scholar 

  • Calne D.B. (1994) Is idiopathic Parkinsonism the consequence of an event or a process? Neurology 44, 5–10.

    PubMed  CAS  Google Scholar 

  • Chiueh C.C., Burns R.S., Markey S.P., Jacobowitz D.M., and Kopin I.J. (1985) Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci. 36, 213–218.

    Article  PubMed  CAS  Google Scholar 

  • Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. (1999a) The substantia nigra of the human brain—I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D-28K immunohistochemistry. Brain 122, 1421–1436.

    Article  PubMed  Google Scholar 

  • Damier P., Hirsch E.C., Agid Y., and Graybiel A.M. (1999b) The substantia nigra of the human brain—II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 122, 1437–1448.

    Article  PubMed  Google Scholar 

  • Ehringer H. and Hornykiewicz O. (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschr. 38, 1236–1239.

    Article  PubMed  CAS  Google Scholar 

  • Elsworth J.D., Taylor J.R., Sladek J.R., Collier T.J., Redmond D.E., and Roth R.H. (2000) Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in Old-World primates one year after MPTP treatment. Neuroscience 95, 399–408.

    Article  PubMed  CAS  Google Scholar 

  • Fearnley J.M. and Lees A.J. (1991) Aging and Parkinson’s disease: substantia nigra regional selectivity. Brain 114, 2283–2301.

    Article  PubMed  Google Scholar 

  • Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69, 1322–1325.

    Article  PubMed  CAS  Google Scholar 

  • German D.C., Dubach M., Askari S., Speciale S.G., and Bowden D.M. (1988b) 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161–174.

    Article  PubMed  CAS  Google Scholar 

  • German D.C., Dubach M., Askari S., Speciale S.G., and Bowden D.M. (1988a) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? Neuroscience 24, 161–174.

    Article  PubMed  CAS  Google Scholar 

  • German D.C., Nelson E.L., Liang C.-L., Speciale S.G., Sinton C.M., and Sonsalla P.K. (1996) The neurotoxin MPTP causes degeneration of specific nucleus A8, A9, and A10 dopaminergic neurons in the mouse. Neurodegeneration 5, 299–312.

    Article  PubMed  CAS  Google Scholar 

  • Gross C.E., Ravenscroft P., Dovero S., Jaber M., Bioulac B., and Bezard E. (2003) Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice. J. Neurochem. 84, 1246–1255.

    Article  PubMed  CAS  Google Scholar 

  • Hantraye P., Varastet M., and Peschanski M. (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53, 169–178.

    Article  PubMed  CAS  Google Scholar 

  • Hassler R. (1938) Zur Pathologie der Paralysis Agitans und des postenzephalitischen Parkinsonismus. J. Psychol. Neurol. 48, 387–476.

    Google Scholar 

  • Hirsch E.C. (1999) Mechanism and consequences of nerve cell death in Parkinson’s disease. J. Neural Transm.—Suppl. 127–137.

  • Hirsch E.C., Graybiel A.M., and Agid Y. (1988) Melanized dopaminergic neurons are differentially affected in Parkinson’s disease. Nature 334, 345–348.

    Article  PubMed  CAS  Google Scholar 

  • Hirsch E.C., Hunot S., Damier P., and Faucheux B. (1998) Glial cells and inflammation in Parkinson’s disease: a role in neurodegeneration? Ann. Neurol. 44, S115-S120.

    PubMed  CAS  Google Scholar 

  • Hoehn H.M. and Yahr M.D. (1967) Parkinsonism: onset, progression and mortablity. Neurology 17, 427–442.

    Article  PubMed  CAS  Google Scholar 

  • Höglinger G.U., Féger J., Pringent A., Michel P.P., Parain K., Champy P., et al. (2003) Chronic systemic complex I inhibition icduces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84, 491–502.

    Article  PubMed  Google Scholar 

  • Hornykiewicz O. and Kish S.J. (1987) Biochemical pathophysiology of Parkinson’s disease, in Parkinson’s disease (Yahr M. and Bergmann K.J., eds.), pp. 19–34. Raven Press, New York.

    Google Scholar 

  • Irwin I., DeLanney L.E., Forno L.S., Finnegan K.T., DiMonte D.A., and Langston J.W. (1990) The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey. Brain Res. 531, 242–252.

    Article  PubMed  CAS  Google Scholar 

  • Kish S.J., Shannak K., and Hornykiewicz O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876–880.

    Article  PubMed  CAS  Google Scholar 

  • Koller W.C., Langston J.W., Hubble J.P., Irwin I., Zack M., Golbe L., et al. (1991) Does a long preclinical period occur in Parkinson’s disease? Neurology 41, 8–13.

    PubMed  CAS  Google Scholar 

  • Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., and Ferrante R.J. (2000) MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211–213.

    Article  PubMed  CAS  Google Scholar 

  • Langston J.W., Ballard P., Tetrud J., and Irwin I. (1983) Chronic parkinsonism in humans due to a product of meperidine-analogysnthesis. Science 219, 979–980.

    Article  PubMed  CAS  Google Scholar 

  • Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46, 598–605.

    Article  PubMed  CAS  Google Scholar 

  • Lee C.S., Schulzer M., Mak E.K., Snow B.J., Tsui J.K., Calne S., et al. (1994) Clinical observations on the rate of progression of idiopathic parkinsonism. Brain 117, 501–507.

    Article  PubMed  Google Scholar 

  • McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. (1988) Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24, 574–576.

    Article  PubMed  CAS  Google Scholar 

  • Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., and Graybiel A.M. (1992) Differential vulnerability of primate caudate-putamen and striosome- matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine. Proc. Natl. Acad Sci. USA 89, 3859–3863.

    Article  PubMed  CAS  Google Scholar 

  • Morrish P.K., Sawle G.V., and Brooks D.J. (1996) An [18F]dopa-PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119, 585–591.

    Article  PubMed  Google Scholar 

  • Parkinson J. (1817) An essay on the Shaking Palsy, Sherwood, Nelly and Jones, London.

    Google Scholar 

  • Perez-Otano I., Oset C., Luquin M.R., Herrero M.T., Obeso J.A., and Del Rio J. (1994) MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci. Lett. 175, 121–125.

    Article  PubMed  CAS  Google Scholar 

  • Prunier C., Bezard E., Montharu J., Marina M., Besnard J.C., Baulieu J.L., et al. (2003) Presymptomatic diagnosis of experimental parkinsonism with 123I-PE21 SPECT. Neuroimage in press.

  • Raff M.C., Whitmore A.V., and Finn J.T. (2002) Axonal self-destruction and neurodegeneration. Science 296, 868–871.

    Article  PubMed  CAS  Google Scholar 

  • Riederer P. and Wuketich S. (1976) Time course of nigrostriatal degeneration in parkinson’s disease. J. Neural Transm. 38, 277–301.

    Article  PubMed  CAS  Google Scholar 

  • Schneider J.S. (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res. 534, 25–36.

    Article  PubMed  CAS  Google Scholar 

  • Schneider J.S., Decamp E., and Wade T. (1999) Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J. Neurosci. 19, 6643–6649.

    PubMed  CAS  Google Scholar 

  • Schneider J.S. and Kovelowski C.J. (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res. Brain Res. 519, 122–128.

    Article  PubMed  CAS  Google Scholar 

  • Schulzer M., Lee C.S., Mak E.K., Vingerhoets F.J.G., and Calne D.B. (1994) A mathematical model of pathogenesis in idiopathic parkinsonism. Brain 117, 509–516.

    Article  PubMed  Google Scholar 

  • Snow B.J., Vingerhoets F.J.G., Langston J.W., Tetrud J.W., Sossi V., and Calne D.B. (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry 68, 313–316.

    Article  PubMed  CAS  Google Scholar 

  • Varastet M., Riche D., Mazière M., and Hantraye P. (1994) Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson’s disease. Neuroscience 63, 47–56.

    Article  PubMed  CAS  Google Scholar 

  • Vingerhoets F.J.G., Snow B.J., Lee C.S., Schulzer M., Mak E., and Calne D.B. (1994) Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann. Neurol. 36, 759–764.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Erwan Bezard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Meissner, W., Prunier, C., Guilloteau, D. et al. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of parkinson’s disease. Mol Neurobiol 28, 209–218 (2003). https://doi.org/10.1385/MN:28:3:209

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1385/MN:28:3:209

Index Entries

Navigation